Alluvium Asset Management, an asset management company, released its “Conventum – Alluvium Global Fund” fourth-quarter 2024 ...

McKesson has been a top-rated stock at MAPsignals for a long time. That means the stock has unusual buy pressure and growing fundamentals. We have a ranking process that showcases stocks like this on ...

McKesson Corporation (MCK ... of growth from GLP-1 medications and a robust oncology network business. Vertex Pharmaceuticals (VRTX) comes in second with a score of 4.04 and a Buy rating given ...

On Thursday, Citi analyst Daniel Grosslight increased the price target for McKesson Corporation (NYSE:MCK) shares to $685 ...

Shares of McKesson Corp. MCK slipped 1.92% to $640.66 Wednesday, on what proved to be an all-around mixed trading session for ...

Wells Fargo raised the firm’s price target on McKesson (MCK) to $691 from $641 and keeps an Equal Weight rating on the shares. The firm’s 2025 ...

McKesson Corp. engages in providing healthcare services. It operates through the following segments: U.S. Pharmaceutical, Prescription Technology Solutions (RxTS), Medical-Surgical Solutions ...

McKesson is a significant player in the healthcare supply chain, providing medical supplies and pharmaceutical products across various regions. The company is essential in the U.S. Pharmaceutical ...

Total revenue fell short of analysts' expectations. Adjusted EPS of $7.88 beat analyst estimates by 9%. The company raised its full-year EPS guidance. Source: Analyst estimates for the quarter ...

With a market cap of $75.6 billion, McKesson delivers pharmaceuticals, medical supplies, and technology solutions that enhance healthcare efficiency and patient outcomes, supporting pharmacies ...